A tiny cluster of brain cells in mice might hold the key to keeping opioids' pain-fighting power while removing their addictive punch. Researchers at Duke University in Durham, North Carolina, have made a discovery that could eventually change how we develop safer painkillers.
The study, published in the journal Nature, found that a specific group of neurons in the brain appears to drive the learning process that can lead to addiction. By blocking opioids' effects just in those cells, scientists prevented mice from forming drug-seeking habits while letting the drugs still relieve pain.
"What's unique about our study is that it shows that dopamine elevation can be separated from learned drug preference," said Mike Tadross, a neurosurgeon and neuroscientist who led the work. "Dopamine isn't enough by itself; opioid reward learning also appears to require a drop in acetylcholine."
To understand why this matters, it helps to know how opioids work. They ease pain in two ways: first, by quieting pain signals in the spinal cord before they reach the brain, and second, by changing how the brain interprets pain signals that do arrive. As Tadross put it, "You may still feel the pain, but you aren't bothered by it." Think of running from a bear and twisting your ankle—you feel it, but you don't care in that moment. That unique ability to rewire pain perception is what makes opioids so powerful for severe pain. But the same brain changes that make people not care about pain also teach the brain to want more of the drug.
Scientists have long blamed dopamine—a brain chemical associated with pleasure and reward—for this learning process. When opioids enter the brain, dopamine surges in a region called the nucleus accumbens, which handles motivation and emotion. But the Duke team discovered that dopamine alone doesn't tell the whole story.
Some neurons in the nucleus accumbens communicate using a different chemical called acetylcholine. Earlier research suggested these cholinergic neurons weren't important for opioid reward learning. But those studies used genetic techniques that permanently removed opioid receptors from the cells at birth, which may have let the brain adapt over time.
Tadross and his team tried a different approach. They used a molecular tool called DART, developed in Tadross's lab, to deliver a version of the opioid reversal drug naloxone that worked only on cholinergic neurons in the nucleus accumbens. The rest of the brain's opioid signaling stayed intact.
The result surprised them. Mice treated this way didn't develop a preference for a chamber where they received morphine—a standard test for reward learning in lab animals. But they still got the same pain relief as untreated mice. The opioid-induced drop in acetylcholine from this small group of neurons may be what helps the brain form drug-seeking associations in the first place.
"That's really exciting because it suggests that you might retain many of the benefits of opioids—even allowing them to do what opioids are so good at doing: to change how pain is perceived in the brain—while potentially making them less addictive," Tadross said.
The findings challenge earlier conclusions and open a new avenue for drug development. The next step would be to see if the same approach works in humans, a process that could take years. But for now, researchers have identified a small target that might one day let us keep the best parts of opioids while leaving the worst behind.